Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H; study investigators. Maertens JA, et al. Among authors: motyl mr. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140-6736(21)00219-1. Lancet. 2021. PMID: 33549194 Clinical Trial.
In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20.
Karlowsky JA, Lob SH, Akrich B, DeRyke CA, Siddiqui F, Young K, Motyl MR, Hawser SP, Sahm DF. Karlowsky JA, et al. Among authors: motyl mr. JAC Antimicrob Resist. 2023 Jan 20;5(1):dlad003. doi: 10.1093/jacamr/dlad003. eCollection 2023 Feb. JAC Antimicrob Resist. 2023. PMID: 36694850 Free PMC article.
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Johnson MG, Bruno C, Castanheira M, Yu B, Huntington JA, Carmelitano P, Rhee EG, De Anda C, Motyl M. Johnson MG, et al. Int J Antimicrob Agents. 2021 Mar;57(3):106278. doi: 10.1016/j.ijantimicag.2021.106278. Epub 2021 Jan 9. Int J Antimicrob Agents. 2021. PMID: 33434676 Free article. Clinical Trial.
119 results